For research use only. Not for therapeutic Use.
DB818 is a potent inhibitor of Homeobox A9 (HOXA9). HOXA9 is a transcription factor regulating haematopoiesis and leukaemia cell proliferation, involving in acute myeloid leukaemia (AML). DB818 inhibits AML cell lines growth, induces apoptosis[1].
DB818 (12.5 mg/kg, 25 mg/kg; s.c.; once daily for 4 days) completely cures Parasitemia in mice infected with B. microti. at dose of 25 mg/kg, while cures 2/3 mice at 12.5 mg/kg[1].
DB818 results recrudescence occurring on mice around day 20 postinfection[1].
| Catalog Number | I042030 |
| CAS Number | 790241-43-9 |
| Synonyms | 2-[5-(4-carbamimidoylphenyl)thiophen-2-yl]-3H-benzimidazole-5-carboximidamide |
| Molecular Formula | C19H16N6S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H16N6S/c20-17(21)11-3-1-10(2-4-11)15-7-8-16(26-15)19-24-13-6-5-12(18(22)23)9-14(13)25-19/h1-9H,(H3,20,21)(H3,22,23)(H,24,25) |
| InChIKey | MSQVFIHMHRAMOC-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C2=CC=C(S2)C3=NC4=C(N3)C=C(C=C4)C(=N)N)C(=N)N |
| Reference | [1]. Sonoda Y, et al. Effects of HOXA9 Inhibitor DB818 on the Growth of Acute Myeloid Leukaemia Cells. Anticancer Res. 2021 Apr;41(4):1841-1847. |
